Belimumab Auto-Injector [Benlysta]

Phase 2

Belimumab Auto-Injector [Benlysta] is one of 8 therapeutic programs targeting Autoimmune Hepatitis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Autoimmune HepatitisRecruiting

Autoimmune HepatitisPhase 2

Recruiting

Competition

Competitive Landscape

7 competitors in Autoimmune Hepatitis

#DrugCompanyPhaseTrials

Cellcept

Roche

Approved

2 2

Neoral

Novartis

Approved

—3

Imuran

LLegacy Health System

Approved

3 4

Rayos

RRoxane Laboratories

Approved

2 5

Prograf

VVeloxis Pharmaceuticals

Approved

1 6

Benlysta

GGlaxo Dba Glaxosmithkline

Phase 2

1 7

Plasma Exchange

Sanofi

Preclinical

1 8

Belimumab Auto-Injector [Benlysta]

UUniversity Health Network, Toronto

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

Phase 2Recruiting

Autoimmune Hepatitis

NCT06381453

Clinical

Trials by Indication[1]

Autoimmune Hepatitis1 trial

Belimumab in the Management of Autoimmune Hepatitis: A Multi-centre, Open-label Trial of add-on Belimumab Therapy to Standard of Care

Recruiting·UUniversity Health Network, Toronto·Phase 2·NCT06381453·48 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Belimumab Auto-Injector [Benlysta]. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Belimumab Auto-Injector [Benlysta]. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — University Health Network, Toronto company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: UUniversity Health Network, Toronto

Belimumab Auto-Injector [Benlysta]

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2029

Trials by Indication[1]

Autoimmune Hepatitis1 trial

References

Drug Info

Quick Facts

Related News